Product name
Diagnosis of Metastases of colon and other cancersSummary
mutations in ß-catenin as diagnostic tool and therapeutic targetOrganization name
ipal GmbHProfile
The technology can distinguish between the mutated so called gain-of-function ß-catenin and the wild type non-mutated ß-catenin. The activated ß-catenin induces a pathway which results in stronger metastasis formation.
Advantages
- Application as diagnostic tool for all ß-catenin associated cancers, e.g. in liver, spleen, lung, heart and brain
- Development of new therapeutic strategies aiming at disruption of the
ß- catenin/S100A4 connection are feasible - Important tool for prevention of colon cancer metastasis
A US patent was filed. Additional information is provided in the attached pdf. The technology was developed at Charite University Hospital Berlin, Germany and is offered by IPAL.
Contact
IPAL GmbH
Dr. Petra Düx
petra.duex(at)ipal.de
About IPAL
The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.
Description File
06122_ss_catenin_TA.pdf
print this page
